WHO ICTRP trial
Thyroid hormone analog therapy of patients with severe psychomotor retardation…
NL-OMON44458 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON44458 |
|---|---|
| Public title | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. |
| Scientific title | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients |
| Primary sponsor | Erasmus MC, Universitair Medisch Centrum Rotterdam |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | Allan-Herndon-Dudley Syndrome MCT8 patient;10014699;10043739;10010335;Allan-Herndon-Dudley Syndrome;MCT8 patient |
| Interventions | Oral tablets of Triac, in 2-5 daily doses, during a study period of 12 months. ;Allan-herndon-Dudley Syndrome;MCT8;Thyroid hormone analog;Triac |
| Registration date | Aug 19, 2016 |
| Target size | 15 |
| Secondary IDs | 2014-000178-20;NCT02060474;NL47771.078.14 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: